Viral infections and anti-viral treatments

Human papillomavirus (HPV)

  • Value cards for human papillomavirus (HPV)
  • Payer value deck and frequently asked questions for HPV and HPV-related diseases
  • Value pack for a HPV vaccine
  • Brief adaptation of a Markov model for a HPV vaccine
  • Update of a budget impact model for a HPV vaccine
  • Cost-effectiveness analysis of a HPV vaccine for Spain
  • HTA submission for a HPV vaccine
  • Manuscript on the German cost-effectiveness analysis of a HPV vaccine
  • Manuscript on the Spanish cost-effectiveness analysis of a HPV vaccine
  • Systematic literature review on the indirect protection from the HPV vaccination
  • Value demonstration and implementation plan for a new HPV test
  • Training sales reps on an interactive model for a HPV vaccine
  • Analysis and reporting on the budget impact of a HPV vaccine
  • One-pager communication tool on cross-protection in HPV
  • One-pager on HPV in head and neck cancer
  • Revision of one-pagers in HPV vaccines
  • Literature review of epidemiology and economic data in HPV
  • Update to European one-pager value communication tools for HPV and for a nine-valent HPV vaccine
  • e-v@luate platform for HPV vaccines
  • Update to a payer value deck in HPV infection
  • Evidence package (literature review and value messages) for HPV vaccination
  • Adaptation of a Markov model on a HPV vaccine to Belgium
  • Development of a rationale for the need for a HPV vaccine
  • Development of a PRO strategy in cervical cancer and HPV
  • Summary report, top-up literature review, meta-analysis, editorial board and manuscripts on HPV infection and cervical cancer

Human immunodeficiency virus (HIV) / Acquired immune deficiency syndrome (AIDS)

  • Business planning toolkit in HIV
  • Development of a payer value story in HIV
  • Payer value story briefing document in HIV
  • Review of an economic model for HIV and submission to the SMC
  • Budget impact model in HIV
  • Targeted literature review of adherence in HIV
  • Targeted literature review in HIV and inflammation
  • Targeted literature synthesis of viral blips and viremia in patients with HIV
  • Literature review on inflammation in patients with HIV
  • Consulting in a multinational case-control study: Impact of side effects on the quality of life (QoL) of HIV patients
  • Advisory board consultation regarding product status and development in HIV
  • General consultancy on PRO endpoints in HIV/AIDS trials
  • Recommendations for the inclusion of PROs into HIV trials
  • Development of an expert report and FDA meeting on tolerability in HIV
  • Consulting on the development of a PRO strategy for international HIV trials with interviews in the US and Puerto Rico
  • Consulting on study documents and development of SAP for psychometric validation of a PRO instrument of tolerability in patients with HIV
  • Preparation and development of a manuscript on HIV Patient Symptom Profile (HIV PSP)
  • Preliminary psychometric validation of the HIV PSP questionnaire using the UK SWITCH study data
  • Analysis of HIV PSP data from the SWITCH study to compare treatment arms
  • Confirming concept definitions of the HIV Treatment Tolerability Index for translation purposes
  • An evidence synthesis on the efficacy and safety of two drugs and protease inhibitors in treatment‑naïve HIV patients
  • Manuscript network meta-analysis of an antiretroviral drug for the treatment of HIV
  • Budget impact tool for an antiretroviral drug for treatment-naive HIV
  • Literature review of the epidemiology and burden of illness in HIV-related neuropathy
  • Top-up literature review, revised manuscript and presentations on HIV and AIDS
  • Development and psychometric validation of a PRO instrument of tolerability in patients with HIV
  • Two abstracts, two posters and a manuscript on the development and psychometric validation of a PRO instrument of tolerability in patients with HIV
  • Selection of PRO measures for HIV trials

Varicella

  • Update to payer value slide deck for varicella
  • Payer value deck for a varicella vaccine
  • Payer material development for vaccines in varicella
  • Response to payer questions deck in varicella
  • e-v@luate platform on vaccines for varicella

Polio

  • Burden of disease literature review on polio in the UK and Ireland

Hepatitis

Hepatitis A

  • Update to payer value deck in Hepatitis A
  • Payer material development for vaccines in hepatitis A
  • e-v@luate platform on vaccines for hepatitis A
  • Burden of disease literature review on hepatitis A in the UK and Ireland

Hepatitis B

  • Systematic literature review of a treatment for chronic hepatitis B
  • Preparation of a NICE submission for a hepatitis B drug
  • SMC submission for a treatment for chronic hepatitis B
  • Database analysis to calculate the economic burden of hepatitis B in the UK

Hepatitis C

  • Therapeutic area strategy analysis and reporting in chronic hepatitis C virus
  • Biomarkers in the treatment of hepatitis C virus infected patients – personalised medicine
  • Maximizing the use of a treatment for hepatitis C-infected patients through personalised medicine – extending the tool to additional treatments
  • Treatment algorithm for hepatitis C treatment
  • One-pager value communication tool for Hepatitis C
  • Comprehensive literature research in chronic hepatitis C in Asian countries
  • Database development and analysis in hepatitis C
  • Concept elicitation and cognitive debriefing interviews with hepatitis C patients in multiple countries
  • Development of an EMA summary document for several instruments used in hepatitis C trials
  • Development of a PRO outcomes summary document and communications support in hepatitis C trials
  • Description, interpretation and analysis of pooled data related to the use of several questionnaires, scales and screening tests in three hepatitis C clinical trials
  • Conceptual model for patients with hepatitis C
  • Psychometric validation of a hepatitis C symptom checklist using phase III trial data
  • Treatment patterns, healthcare utilization and costs associated with the hepatitis C virus in Japan
  • Selection of PRO measures for hepatitis C trials

Yellow fever

  • Burden of disease literature review on yellow fever in the UK and Ireland

Rabies

  • Burden of disease literature review on rabies in the UK and Ireland

Respiratory syncytial virus

  • Core value dossier for a treatment for respiratory syncytial virus
  • Core value dossier update in respiratory syncytial virus prophylaxis to support the roll-out of a new liquid formation
  • Value dossier update on respiratory syncytial virus
  • Payer objection handlers to support treatment in secondary hyperparathyroidism (SHPT) and respiratory syncytial virus
  • Economic evaluation of a treatment for respiratory syncytial virus
  • Observational study and claims analysis of respiratory distress in infants with respiratory syncytial virus
  • Development of an evidence package for a COA strategy for paediatric respiratory syncytial virus
  • Content validation of a COA strategy for paediatric respiratory syncytial virus
  • Exit interviews with caregivers and clinicians in a prospective study to assess the Paediatric Respiratory Syncytial Virus Electronic Severity and Outcome Rating System (PRESORS)
  • Content validation of a COA strategy for respiratory synctial virus in the elderly or in those with respiratory compromise

Dengue disease

  • Finalization and validation of a PRO instrument for measurement of burden in Dengue disease

Measles, mumps and rubella (MMR)

  • One-pager value communication tool for the measles, mumps and rubella (MMR) vaccine
  • Payer value deck for an MMR vaccine
  • e-v@luate platform on vaccines for MMR

Herpes zoster (shingles)

  • Payer communications on herpes zoster
  • Payer communications on a herpes zoster vaccine
  • A review of HTA guidance in nine countries to determine requirements for indirect costs in herpes zoster
  • Review of cost-effectiveness studies in post-herpetic neuralgia (PHN)
  • PRO literature review, instrumentation, gap analysis and recommendations in herpes zoster and post-herpetic neuralgia (PHN)
  • Development of a conference abstract and poster on herpes zoster and post-herpetic neuralgia
  • Development of two manuscripts on a herpes zoster study
  • Literature review investigating the burden of disease of herpes zoster and post-herpetic neuralgia in Europe
  • Systematic literature review on the caregiver burden in herpes zoster (shingles) and post-herpetic neuralgia
  • Searches to update a critical review of evidence documenting the humanistic, economic and societal burden of herpes zoster in Europe
  • Research study on the impact on quality of life in herpes zoster
  • Systematic literature review report on herpes zoster
  • Validation of the Numerical Rating Scale (NRS) in post-herpetic neuralgia
  • Payer material development for vaccines in shingles
  • e-v@luate platform on vaccines for shingles

Rotavirus

  • Payer material development for vaccines in rotavirus gastroenteritis (RVGE)
  • e-v@luate platform on a vaccine for rotavirus

Influenza

  • Upgrade of current model-structure and sensitivity analysis in influenza
  • Adaptation of a cost effectiveness model for an influenza vaccine for Germany, Austria and Mexico
  • Two manuscripts on an influenza vaccine for patients at risk and patients over 65 years old in France
  • Conference poster on the cost effectiveness of adjuvant influenza vaccination in France
  • Update of a value dossier on an influenza vaccine
  • Cost-effectiveness analysis of an influenza vaccine
  • Modification of the SIR dynamic model to the SEIR model for the USA and Italy
  • Modelling of influenza coverage rates
  • Communication of influenza coverage rates within the European Union
  • Book chapter written on the economics of influenza
  • Review of influenza vaccine uptake data
  • Updating an economic model of influenza vaccination (phase 1) – update of a model in patients aged over 65 years in France and the UK
  • Economic evaluation of a workplace influenza vaccination in Russia
  • Communication of the economics of an influenza vaccine
  • Interactive model on influenza
  • Adaptation of an influenza vaccine model to Belgium
  • Positioning paper on influenza
  • Economic value dossiers for influenza vaccines in a) an unprimed paediatric population and b) a primed school age population (intranasal delivery) including literature review, gap analysis and recommendations
  • Literature research and reporting on epidemiology and the economic burden of influenza B in Japan
  • Modification of a SIR dynamic model to a SEIR model for the US and Italy
  • Dynamic model to inform internal decision making regarding pandemic influenza
  • Regulatory support for the validation of a questionnaire for influenza vaccination